Orbeos (Atorvastatin)

Atorvastatin blocks the enzyme HMG‑CoA reductase in the liver, which is essential for cholesterol synthesis. By reducing cholesterol production, the liver increases the number of LDL receptors, enhancing removal of LDL cholesterol from the bloodstream and thereby lowering overall plasma cholesterol.

The exact dose of Orbeos is determined by the prescribing clinician based on the patient’s cholesterol levels, cardiovascular risk profile, and tolerance. Typical starting doses range from low to moderate strengths, with adjustments made according to therapeutic response and safety monitoring.

The safety of atorvastatin during pregnancy and lactation has not been established. It is generally avoided unless the potential benefit justifies the possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To order Orbeos, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Orbeos (atorvastatin) is a high‑potency statin with a longer half‑life than many alternatives such as simvastatin, allowing once‑daily dosing and greater LDL‑cholesterol reduction at comparable doses. Its metabolic profile differs, leading to distinct interaction potentials, especially with CYP3A4 inhibitors.

Orbeos tablets should be stored at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Orbeos is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their clinician and not split or crush the tablet unless instructed.

The most serious adverse events include rhabdomyolysis, a severe muscle breakdown that can lead to kidney failure, and significant liver injury indicated by marked elevations in hepatic enzymes. Prompt medical attention is required if patients experience unexplained muscle pain, weakness, or jaundice.

Orbeos is contraindicated in patients with active liver disease, unexplained persistent elevations of serum transaminases, known hypersensitivity to atorvastatin or any excipients, and in individuals who are pregnant or breastfeeding unless the benefits outweigh the risks.